Processa acquires Vidya in a stock-for-stock deal, adding a differentiated BTK inhibitor and securing $200M in financing to fund parallel phase II studies in food allergy, CSU, and MS, with data expected in 2027–2028. The deal targets large unmet needs and multi-billion dollar markets.Based on Proc…
Processa acquires Vidya in a stock-for-stock deal, adding a differentiated BTK inhibitor and securing $200M in financing to fund parallel phase II studies in food allergy, CSU, and MS, with data expected in 2027–2028. The deal targets large unmet needs and multi-billion dollar markets.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
